217 related articles for article (PubMed ID: 34716214)
1. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.
Sharma A; Zheng Y; Ezekowitz JA; Westerhout CM; Udell JA; Goodman SG; Armstrong PW; Buse JB; Green JB; Josse RG; Kaufman KD; McGuire DK; Ambrosio G; Chuang LM; Lopes RD; Peterson ED; Holman RR
Diabetes Care; 2022 Jan; 45(1):204-212. PubMed ID: 34716214
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.
Stevens SR; Segar MW; Pandey A; Lokhnygina Y; Green JB; McGuire DK; Standl E; Peterson ED; Holman RR
Cardiovasc Diabetol; 2022 Aug; 21(1):166. PubMed ID: 36030198
[TBL] [Abstract][Full Text] [Related]
3. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
4. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
Pagidipati NJ; Zheng Y; Green JB; McGuire DK; Mentz RJ; Shah S; Aschner P; Delibasi T; Rodbard HW; Westerhout CM; Holman RR; Peterson ED;
Am Heart J; 2020 Jan; 219():47-57. PubMed ID: 31707324
[TBL] [Abstract][Full Text] [Related]
5. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Holman RR; Bethel MA; George J; Sourij H; Doran Z; Keenan J; Khurmi NS; Mentz RJ; Oulhaj A; Buse JB; Chan JC; Iqbal N; Kundu S; Maggioni AP; Marso SP; Öhman P; Pencina MJ; Poulter N; Porter LE; Ramachandran A; Zinman B; Hernandez AF
Am Heart J; 2016 Apr; 174():103-10. PubMed ID: 26995376
[TBL] [Abstract][Full Text] [Related]
8. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
Scheen AJ; Paquot N
Rev Med Liege; 2015 Oct; 70(10):511-6. PubMed ID: 26727841
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Green JB; Bethel MA; Paul SK; Ring A; Kaufman KD; Shapiro DR; Califf RM; Holman RR
Am Heart J; 2013 Dec; 166(6):983-989.e7. PubMed ID: 24268212
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Engel SS; Green JB; Huang Z; Josse RG; Kaufman KD; Standl E; Suryawanshi S; Van de Werf F; McGuire DK; Peterson ED; Holman RR;
Diabetes Care; 2017 Apr; 40(4):494-501. PubMed ID: 28057693
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
Alfredsson J; Green JB; Stevens SR; Reed SD; Armstrong PW; Angelyn Bethel M; Engel SS; McGuire DK; Van de Werf F; Hramiak I; White HD; Peterson ED; Holman RR;
Diabetes Obes Metab; 2018 Oct; 20(10):2379-2388. PubMed ID: 29923323
[TBL] [Abstract][Full Text] [Related]
12. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
13. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
Standl E; Stevens SR; Armstrong PW; Buse JB; Chan JCN; Green JB; Lachin JM; Scheen A; Travert F; Van de Werf F; Peterson ED; Holman RR;
Diabetes Care; 2018 Mar; 41(3):596-603. PubMed ID: 29311155
[TBL] [Abstract][Full Text] [Related]
14. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
Sharma A; Green JB; Dunning A; Lokhnygina Y; Al-Khatib SM; Lopes RD; Buse JB; Lachin JM; Van de Werf F; Armstrong PW; Kaufman KD; Standl E; Chan JCN; Distiller LA; Scott R; Peterson ED; Holman RR;
Diabetes Care; 2017 Dec; 40(12):1763-1770. PubMed ID: 28986504
[TBL] [Abstract][Full Text] [Related]
15. Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks.
Chen TH; Wang CC; Liu CH; Hsiao CC; Chen ST; Liu FH; Ho MY; Li YR
Endocr Pract; 2020 Aug; 26(8):818-829. PubMed ID: 33471673
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
[TBL] [Abstract][Full Text] [Related]
18. Coronary artery calcium, hepatic steatosis, and atherosclerotic cardiovascular disease risk in patients with type 2 diabetes mellitus: Results from the Dallas heart study.
Khawaja T; Linge J; Leinhard OD; Al-Kindi SG; Rajagopalan S; Khera A; de Lemos JA; Joshi P; Neeland IJ
Prog Cardiovasc Dis; 2023; 78():67-73. PubMed ID: 36931545
[TBL] [Abstract][Full Text] [Related]
19. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
McAlister FA; Zheng Y; Westerhout CM; Buse JB; Standl E; McGuire DK; Van de Werf F; Green JB; Armstrong PW; Holman RR;
Eur J Heart Fail; 2020 Nov; 22(11):2026-2034. PubMed ID: 32621557
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Green JB; Merrill P; Lokhnygina Y; Mentz RJ; Alfredsson J; Holman RR;
Diabetes Obes Metab; 2023 Jun; 25(6):1473-1484. PubMed ID: 36700460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]